BofA downgraded Erasca (ERAS) to Underperform from Buy with a price target of $1.50, down from $4.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ERAS:
- Erasca downgraded to Equal Weight from Overweight at Morgan Stanley
- Cautious Outlook on Erasca Due to Strategic Shifts and Delayed Clinical Data
- Erasca’s Strategic Advancements in RAS Programs Justify Buy Rating
- Erasca Reports Progress and Financial Stability in Q2 2025
- Erasca files $500M mixed securities shelf